Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod presented at the ECC conference
28 September 2015 - 4:39PM
Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces, at the
European Cancer Congress (ECC 2015) held in Vienna 25-29 September,
the presentation of final results from the 10TASQ10 tasquinimod
phase 3 trial.
Final results show that tasquinimod treatment
resulted in a prolonged radiographic progression free survival
(rPFS), 7.0 vs. 4.4 months (central assessment) similar to an
earlier Phase 2 study. However, the positive effect on rPFS did not
translate into an improved OS (HR 1.097, 95% CI: 0.938-1.282).
Tasquinimod safety was in general manageable and similar to what
was observed during the Phase 2 study.
The abstract "A phase 3, randomized, double-blind,
placebo-controlled study of tasquinimod (TASQ) in men with
metastatic castrate resistant prostate cancer (mCRPC), M. Carducci
et al" was selected by the 18th ECCO - 40th ESMO European
Cancer Congress Scientific Committee as a Best Abstract
presentation in a Presidential Session (28 September 2015 at 2:35
pm CEST).
About tasquinimod
Tasquinimod is a novel oral immunotherapy that
targets the tumor microenvironment by binding to S100A9 and
modulating regulatory myeloid cell functions, exerting
immunomodulatory, anti-angiogenic and anti-metastatic properties.
The development of tasquinimod principally has been focused on the
treatment of prostate cancer, but early clinical studies in other
cancer indications has been performed.
About the 10TASQ10 trial
The 10TASQ10 trial is a randomized,
double-blind, placebo-controlled, global Phase III clinical trial
which evaluated tasquinimod in patients with metastatic castration
resistant prostate cancer (mCRPC) who had not yet received
chemotherapy. The aim of the 10TASQ10 study was to confirm
tasquinimod's efficacy, with radiological Progression Free Survival
(rPFS) as primary endpoint and overall survival (OS) as key
secondary endpoint. In April 2015, top line data was presented
which showed that tasquinimod reduced the risk of radiographic
cancer progression or death compared to placebo (rPFS, HR=0.69, CI
95%: 0.60 - 0.80) in patients with metastatic castration resistant
prostate cancer (mCRPC) who have not received chemotherapy, but did
not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28). The
efficacy results did not support positive benefit risk balance in
this patient population.
For further information, please contact:
Tomas Leanderson, President & CEO Tel +46 46 19 20 95
Hans Kolam, CFO Tel +46 46 19 20 44
Active Biotech AB (publ) (Nasdaq
Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal phase III development for the treatment
of relapsing remitting multiple sclerosis. Also, laquinimod is in
phase II development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are ongoing for the projects ISI, ANYARA and
paquinimod. Please visit www.activebiotech.com for more
information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11
00
Active Biotech's Safe
Harbor Statement in Accordance with the Swedish Securities Market
Act: This press release contains
certain forward-looking statements. Such forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ
materially from any future results, performance or achievement
implied by the forward-looking statements. The company does not
undertake any obligation to update or publicly release any
revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this
press release.
Active Biotech is obligated to publish the information contained
in this press release in accordance with the Swedish Securities
Market Act and/or the Financial Instruments Trading Act . This
information was provided to the media for publication at 8:30 a.m.
CEST on Sep 28, 2015.
Final results from Active Biotech's
10TASQ10 Phase 3
http://hugin.info/1002/R/1953201/710729.pdf
HUG#1953201
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024